Background:Heme is a metallo‐compound, essential for the survival of most organisms. However, the ability of the central iron (Fe) atom, contained within its protoporphyrin ring, to participate in the Fenton reaction and generate highly reactive hydroxyl radicals renders heme potentially toxic. Under inflammatory conditions, the release of heme from hemoproteins leads to an exacerbated oxidative stress, a deleterious effect associated with tissue damage and disease severity.Aims:As immune‐mediated inflammatory diseases often cause a certain degree of hemolysis and vascular leakage, it is reasonable to assume that the cytotoxicity of heme/Fe may also affect less accessible organs, such as the brain, thus increasing the risk and severity of neurodegenerative diseases.Methods:This hypothesis has been investigated in mice, in which the exogenous administration of heme or the release of this molecule upon inflammation/infectionwas shown to enhance the severity of Parkinson's disease (PD). An increased susceptibility to pharmacologic PD was observed when mice are exposed to heme and subsequently treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP), a neurotoxin precursor that, once converted into the active metabolite, irreversibly damages the dopaminergic neurons (DNs).Results:Our results demonstrate that from circulation, heme is capable to enter the brain and trigger neuroinflammation. While this is associated with the recruitment of immune cells, which breach the BBB and enter the brain, an increased level of circulating heme was shown to contribute to the occurrence of brain Fe overload, causing an exacerbated locomotor dysfunction in response to PD induction.Summary/Conclusion:Therefore, our findings suggest that the release of heme in circulation upon immune‐mediated inflammatory diseases is capable to prime the brain and contribute to the development of neurodegenerative diseases, such as PD.